Physician profile
Jonathan C Schell
NPI 1265631568
$2,665.08
in general payments reported to CMS, 2019-2025
21 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $219 · 2021: $527 · 2022: $398 · 2023: $526 · 2024: $207 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $385.62 | 2023-2025 | Stellaris, Envista Envy Iol, Envista Mx60 Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $348.79 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $312.48 | 2019-2023 | Tecnis Iol, Catalys System |
| Abbvie INC. | $276.61 | 2022-2025 | |
| Alcon Vision LLC | $238.84 | 2019-2025 | Hydrus Microstent, Clareon |
| Mallinckrodt Hospital Products INC. | $184.33 | 2023 | Acthar |
| Glaukos Corporation | $183.49 | 2021-2025 | Idosetr, Istent Infinite |
| Rxsight INC | $137.93 | 2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Ocular Therapeutix, INC. | $125.00 | 2022 | |
| Carl Zeiss Meditec, INC. | $110.35 | 2021 | |
| Aerie Pharmaceuticals, INC. | $60.47 | 2019-2020 | |
| Biotissue Holdings INC. | $55.06 | 2019-2020 | |
| Carl Zeiss Meditec USA, INC. | $48.28 | 2023 | Lumera 700 |
| The Cameron-Ehlen Group, INC. | $43.22 | 2020 | |
| Astellas Pharma US INC | $32.58 | 2024 | Izervay |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31.54 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $27.42 | 2024 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $17.62 | 2019 | |
| Thea Pharma INC. | $15.61 | 2023 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $15.58 | 2024 | |
| Sight Sciences, INC. | $14.26 | 2024 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Schell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.